SHS invests in heart implant developer CoreMedic

The undisclosed amount of fresh capital will be used to further develop the company's main product group ChordArt. The funding has been provided by the GP's fourth fund SHS IV Fonds, which held a close on €125m in May 2015.

The GP is currently focusing on expanding and financing its portfolio companies. In the upcoming months, SHS plans to make further investments in medical technology and life sciences in the DACH region.

Company
CoreMedic is a startup that develops ChordArt, a group of heart valve repair systems that provide treatment for heart valve malfunctions and other cardiac issues. The company was founded in 2012 and is based in Bern, Switzerland.

People
CoreMedic – Thomas Bauer (CEO).
SHS Gesellschaft für Beteiligungsmanagement – Hubertus Leonhardt (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Switzerland